Adipositas - Ursachen, Folgeerkrankungen, Therapie 2021; 15(03): 149
DOI: 10.1055/s-0041-1735668
Abstracts
Wiesbaden: Adipositas-Kongress 2021

2 Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide 2.4 mg in Adults With Overweight or Obesity (STEP 1)

John Wilding
1   University of Liverpool, Liverpool, Vereinigtes Königreich
,
Rachel Batterham
2   University College London and National Institute of Health Research, London, Vereinigtes Königreich
,
Salvatore Calanna
3   Novo Nordisk, Soborg, Dänemark
,
Melanie Davies
4   Leicester General Hospital, Leicester, Vereinigtes Königreich
,
Luc Van Gaal
5   University of Antwerp, Edegem, Belgien
,
Ildiko Lingvay
6   Southwestern Medical Center, Dallas, USA
,
Tanja Wiedenmann
7   Novo Nordisk Pharma GmbH, Mainz, Deutschland
,
Barbara McGowan
8   Guy’s and St Thomas’ NHS Foundation Trust, London, Vereinigtes Königreich
,
Julio Rosenstock
9   Dallas Diabetes Research Center , Dallas, USA
,
Marie Tran
3   Novo Nordisk, Soborg, Dänemark
,
Thomas Wadden
10   University of Pennsylvania, Philadelphia, USA
,
Sean Wharton
11   McMaster University and Wharton Weight Management Clinic, Toronto, Kanada
,
Koutaro Yokote
12   Chiba University Hospital, Chiba, Japan
,
Niels Zeuthen
3   Novo Nordisk, Soborg, Dänemark
,
Robert Kushner
13   Northwestern University, Chicago, USA
› Author Affiliations
› Further Information
Also available at
 

Zusammenfassung

In adults with overweight or obesity, once-weekly s.c. semaglutide 2.4 mg plus lifestyle intervention induced a mean weight loss of approximately 15% by week 68. Clinically beneficial weight loss of≥10% was achieved by over two-thirds of participants.



Publication History

Article published online:
24 September 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany